Stuart L. Emanuel

2.5k total citations
42 papers, 1.9k citations indexed

About

Stuart L. Emanuel is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Stuart L. Emanuel has authored 42 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 21 papers in Oncology and 14 papers in Organic Chemistry. Recurrent topics in Stuart L. Emanuel's work include HER2/EGFR in Cancer Research (8 papers), Cancer-related Molecular Pathways (8 papers) and Angiogenesis and VEGF in Cancer (7 papers). Stuart L. Emanuel is often cited by papers focused on HER2/EGFR in Cancer Research (8 papers), Cancer-related Molecular Pathways (8 papers) and Angiogenesis and VEGF in Cancer (7 papers). Stuart L. Emanuel collaborates with scholars based in United States, Germany and United Kingdom. Stuart L. Emanuel's co-authors include Peter J. Connolly, Steven A. Middleton, Angel R. Fuentes‐Pesquera, Ronghui Lin, Robert H. Gruninger, Shenlin Huang, Sidney Pestka, Yanhua Lü, Mary Adams and Linda K. Jolliffe and has published in prestigious journals such as Cell, Journal of Biological Chemistry and Cancer Research.

In The Last Decade

Stuart L. Emanuel

42 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stuart L. Emanuel United States	24	765	763	565	239	149	42	1.9k
Joseph Schoepfer Switzerland	24	532 0.7×	1.5k 2.0×	470 0.8×	115 0.5×	209 1.4×	43	2.0k
R.J. Skene United States	22	485 0.6×	1.4k 1.8×	816 1.4×	142 0.6×	209 1.4×	34	2.5k
Christian Grütter Germany	25	483 0.6×	1.4k 1.8×	400 0.7×	370 1.5×	301 2.0×	30	2.0k
Elisa Nuti Italy	30	537 0.7×	1.1k 1.5×	857 1.5×	169 0.7×	114 0.8×	92	2.2k
Guido Bold Switzerland	25	758 1.0×	907 1.2×	490 0.9×	74 0.3×	84 0.6×	46	1.8k
Douglas R. Dougan United States	19	378 0.5×	918 1.2×	293 0.5×	118 0.5×	152 1.0×	32	1.6k
Jennifer J. Bouska United States	23	851 1.1×	1.1k 1.4×	643 1.1×	101 0.4×	197 1.3×	41	2.1k
Kathleen Aertgeerts United States	19	343 0.4×	1.1k 1.5×	833 1.5×	100 0.4×	239 1.6×	31	2.3k
Sanjeev Shangary United States	22	721 0.9×	1.9k 2.5×	1.1k 2.0×	203 0.8×	141 0.9×	30	2.9k
Steven K. Davidsen United States	31	1000 1.3×	1.9k 2.4×	702 1.2×	109 0.5×	178 1.2×	80	3.0k

Countries citing papers authored by Stuart L. Emanuel

Since Specialization

Citations

This map shows the geographic impact of Stuart L. Emanuel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stuart L. Emanuel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stuart L. Emanuel more than expected).

Fields of papers citing papers by Stuart L. Emanuel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stuart L. Emanuel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stuart L. Emanuel. The network helps show where Stuart L. Emanuel may publish in the future.

Co-authorship network of co-authors of Stuart L. Emanuel

This figure shows the co-authorship network connecting the top 25 collaborators of Stuart L. Emanuel. A scholar is included among the top collaborators of Stuart L. Emanuel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stuart L. Emanuel. Stuart L. Emanuel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Haiqing, Lifei Wang, Kai Cao, et al.. (2012). Development of a Carbon-14 Labeling Approach to Support Disposition Studies with a Pegylated Biologic. Drug Metabolism and Disposition. 40(9). 1677–1685. 5 indexed citations

Wong, Tai W., Francis Y. Lee, Stuart L. Emanuel, et al.. (2011). Antitumor and Antiangiogenic Activities of BMS-690514, an Inhibitor of Human EGF and VEGF Receptor Kinase Families. Clinical Cancer Research. 17(12). 4031–4041. 18 indexed citations

Xu, Guozhang, Terry V. Hughes, Peter J. Connolly, et al.. (2008). Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases. Bioorganic & Medicinal Chemistry Letters. 18(12). 3495–3499. 48 indexed citations

Hughes, Terry V., Guozhang Xu, Steven K. Wetter, et al.. (2008). A novel 5-[1,3,4-oxadiazol-2-yl]-N-aryl-4,6-pyrimidine diamine having dual EGFR/HER2 kinase activity: Design, synthesis, and biological activity. Bioorganic & Medicinal Chemistry Letters. 18(17). 4896–4899. 24 indexed citations

Xu, Guozhang, M.C. Abad, Peter J. Connolly, et al.. (2008). 4-Amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(16). 4615–4619. 80 indexed citations

Hughes, Terry V., Stuart L. Emanuel, Peter J. Connolly, et al.. (2008). 7-[1H-Indol-2-yl]-2,3-dihydro-isoindol-1-ones as dual Aurora-A/VEGF-R2 kinase inhibitors: Design, synthesis, and biological activity. Bioorganic & Medicinal Chemistry Letters. 18(18). 5130–5133. 16 indexed citations

Huang, Shenlin, Ronghua Li, Peter J. Connolly, et al.. (2007). Synthesis and biological study of 2-amino-4-aryl-5-chloropyrimidine analogues as inhibitors of VEGFR-2 and cyclin dependent kinase 1 (CDK1). Bioorganic & Medicinal Chemistry Letters. 17(8). 2179–2183. 11 indexed citations

Huang, Shenlin, Ronghui Lin, Yang Yu, et al.. (2007). Synthesis of 3‐(1H‐Benzimidazol‐2‐yl)‐5‐isoquinolin‐4‐ylpyrazolo[1,2‐b]pyridine, a Potent Cyclin Dependent Kinase 1 (CDK1) Inhibitor.. ChemInform. 38(29). 1 indexed citations

Emanuel, Stuart L., Terry V. Hughes, Mary Adams, et al.. (2007). Cellular and in Vivo Activity of JNJ-28871063, A Nonquinazoline Pan-ErbB Kinase Inhibitor That Crosses the Blood-Brain Barrier and Displays Efficacy against Intracranial Tumors. Molecular Pharmacology. 73(2). 338–348. 30 indexed citations

10.

Huang, Shenlin, Ronghua Li, Peter J. Connolly, Stuart L. Emanuel, & Steven A. Middleton. (2006). Synthesis of 2-amino-4-(7-azaindol-3-yl)pyrimidines as cyclin dependent kinase 1 (CDK1) inhibitors. Bioorganic & Medicinal Chemistry Letters. 16(18). 4818–4821. 19 indexed citations

11.

Huang, Shenlin, Ronghui Lin, Yang Yu, et al.. (2006). Synthesis of 3-(1H-benzimidazol-2-yl)-5-isoquinolin-4-ylpyrazolo[1,2-b]pyridine, a potent cyclin dependent kinase 1 (CDK1) inhibitor. Bioorganic & Medicinal Chemistry Letters. 17(5). 1243–1245. 101 indexed citations

12.

Huang, Shenlin, Ronghua Li, Peter J. Connolly, et al.. (2006). Synthesis and biological study of 4-aminopyrimidine-5-carboxaldehyde oximes as antiproliferative VEGFR-2 inhibitors. Bioorganic & Medicinal Chemistry Letters. 16(23). 6063–6066. 21 indexed citations

13.

Huang, Shenlin, et al.. (2006). Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621. Bioorganic & Medicinal Chemistry Letters. 16(14). 3639–3641. 40 indexed citations

14.

Lin, Ronghui, Yanhua Lü, Steven K. Wetter, et al.. (2005). 3-Acyl-2,6-diaminopyridines as cyclin-dependent kinase inhibitors: synthesis and biological evaluation. Bioorganic & Medicinal Chemistry Letters. 15(9). 2221–2224. 21 indexed citations

15.

Zhang, Han‐Cheng, Hong Ye, David F. McComsey, et al.. (2003). Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3. Bioorganic & Medicinal Chemistry Letters. 13(18). 3049–3053. 52 indexed citations

16.

Grant, Elfrida R., Stuart L. Emanuel, Daniel Benjamin, et al.. (2001). Protection against glutamate toxicity through inhibition of the p44/42 mitogen-activated protein kinase pathway in neuronally differentiated P19 cells22Abbreviations: AMPA, (±)-α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid; NMDA, N-methyl-d-aspartate; MAP, mitogen-activated protein; ERK1/2, extracellular signal regulated kinase 1/2; MEK, mitogen-activated protein kinase kinase; JNK, Jun N-terminal kinase; NO, nitric oxide; CDK1, cyclin-dependent kinase I; PKA, protein kinase A; PKC, protein kinase C; CK1/2, casein kinase 1/2; EGFR, epidermal growth factor receptor; CaM-K, calcium/calmodulin-dependent kinase; ATRA, all-trans-retinoic acid; RT-PCR, reverse transcriptase-polymerase chain reaction; and CFDA, carboxyfluorescein diacetate.. Biochemical Pharmacology. 62(3). 283–296. 24 indexed citations

17.

Emanuel, Stuart L., Jeffry R. Cook, Jules O’Rear, Rodney Rothstein, & Sidney Pestka. (1995). New vectors for manipulation and selection of functional yeast artificial chromosomes (YACs) containing human DNA inserts. Gene. 155(2). 167–174. 12 indexed citations

18.

Soh, Jaemog, Robert Donnelly, Serguei V. Kotenko, et al.. (1994). Identification and sequence of an accessory factor required for activation of the human interferon γ receptor. Cell. 76(5). 793–802. 222 indexed citations

19.

Cook, Jeffry R., Stuart L. Emanuel, & Sidney Pestka. (1993). Yeast artificial chromosome fragmentation vectors that utilize URA3 selection. Genetic Analysis Biomolecular Engineering. 10(5). 109–112. 7 indexed citations

20.

Emanuel, Stuart L. & Sidney Pestka. (1993). Amplification of specific gene products from human serum. Genetic Analysis Biomolecular Engineering. 10(6). 144–146. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact